2021
DOI: 10.1136/sextrans-2021-055301
|View full text |Cite
|
Sign up to set email alerts
|

Effect of dupilumab on genital condylomata: a case report

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 6 publications
0
3
0
Order By: Relevance
“…In the current case, remission of GV was achieved, and his BP was treated successfully with dupilumab. Although remission has been observed similarly in patients with atopic dermatitis, authors tend to attribute the phenomenon to the improvement in skin barrier function ( 6 , 7 ). In the current patient, all GV lesions occurred in the BP-free area.…”
Section: Discussionmentioning
confidence: 99%
“…In the current case, remission of GV was achieved, and his BP was treated successfully with dupilumab. Although remission has been observed similarly in patients with atopic dermatitis, authors tend to attribute the phenomenon to the improvement in skin barrier function ( 6 , 7 ). In the current patient, all GV lesions occurred in the BP-free area.…”
Section: Discussionmentioning
confidence: 99%
“…6,7 Shortlisting dupilumab as an anti-wart remedy would, therefore, be welcomed news for patients and doctors (and the manufacturer) alike. In fact, two other cases of cutaneous 8 or genital 9 warts and seven cases of disseminated molluscum, [10][11][12][13] which cleared in AD patients undergoing dupilumab therapy, were reported previously.…”
mentioning
confidence: 99%
“…Indeed, many positive treatment responses have been reported, including resolution of longstanding warts and molluscum. 4,5 Phase III safety data relating to dupilumab for children aged ≥6 months to <6 years have been published following the revolutionizing atopic dermatitis conference. The incidence of herpes virus infection was slightly higher among patients receiving dupilumab (6.0%; 5/83) compared with those receiving a placebo (5.1%; 4/78), but the difference amounted to <1%.…”
mentioning
confidence: 99%